[Use of Bone Morphogenetic Proteins (BMPs) for the Treatment of Pseudarthroses - Efficiency and Therapy Failure].
In the therapy for pseudarthroses of the proximal tibia, the human recombinant bone morphogenetic proteins (BMP-2 and BMP-7) have been used for several years. Despite their limited and specified use as local mediators of bone healing, no conclusions regarding the therapeutic success can be made beforehand. The regulatory mechanisms have turned out to be much more complex and patient-specific than had been assumed before. To help understand the cell biological processes (signalling) and the current possibilities of predicting a successful use of BMP, this article summarises the relevant findings.
BG Trauma Center, Eberhard-Karls-Universität Tübingen.
M
M
Hausmann
BG Trauma Center, Eberhard-Karls-Universität Tübingen.
S
S
Ehnert
BG Trauma Center, Eberhard-Karls-Universität Tübingen.
V
V
Hofmann
BG Trauma Center, Eberhard-Karls-Universität Tübingen.
S
S
Döbele
BG Trauma Center, Eberhard-Karls-Universität Tübingen.
T
T
Freude
BG Trauma Center, Eberhard-Karls-Universität Tübingen.
U
U
Stöckle
BG Trauma Center, Eberhard-Karls-Universität Tübingen.
A
A
Nussler
D000818:Animals; D001846:Bone Development / Q000187:drug effects* / Q000502:physiology*; D019485:Bone Morphogenetic Proteins / Q000378:metabolism* / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D017102:Fracture Healing / Q000187:drug effects; D006801:Humans; D008954:Models, Biological; D011542:Pseudarthrosis / Q000188:drug therapy* / Q000503:physiopathology*; D017211:Treatment Failure; D016896:Treatment Outcome
D019485:Bone Morphogenetic Proteins